Literature DB >> 22576905

Systematic review of medical therapy to prevent recurrent diverticulitis.

Cagdas Unlü1, Lidewine Daniels, Bart C Vrouenraets, Marja A Boermeester.   

Abstract

AIM AND
BACKGROUND: One of today's controversies remains the prevention of recurrent diverticulitis. Current guidelines advise a conservative approach, based on studies showing low recurrence rates and a high operative morbidity and mortality. Conservative measures in prevention recurrence are dietary advises and medical therapies, including probiotics and 5-aminosalicylic acid.
OBJECTIVES: The aim of this systematic review is to assess whether medical or dietary therapies can prevent recurrent diverticulitis after a primary episode of acute diverticulitis. METHOD AND SEARCH STRATEGY: We searched different databases for papers published between January 1966 and January 2011. STUDY SELECTION: Clinical studies were eligible for inclusion if they assessed the prevention of recurrent diverticulitis with a medical or dietary therapy. Exclusion criteria were studies without a control group.
RESULTS: Three randomized controlled trials (RCT), all with a Jadad quality score of 2 out of 5, were included in this systematic review. Mesalazine results in significantly less disease recurrence and fewer symptoms after an acute episode. The use of probiotics decreases symptoms but does not reduce recurrence. No difference in effect is seen when Balsalazide is added to probiotics compared to probiotics only. No relevant studies on dietary therapy/advices or antibiotics for prevention of recurrent diverticulitis were found.
CONCLUSION: The evidence that supports medical therapy to prevent recurrent diverticulitis is of poor quality. Treatment with 5-aminosalicylic acid seems promising. Based on current data, no recommendation of any non-operative relapse prevention therapy for diverticular disease can be made.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22576905     DOI: 10.1007/s00384-012-1486-7

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  34 in total

1.  Diagnosis and management of diverticular disease of the colon in adults. Ad Hoc Practice Parameters Committee of the American College of Gastroenterology.

Authors:  N H Stollman; J B Raskin
Journal:  Am J Gastroenterol       Date:  1999-11       Impact factor: 10.864

2.  Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study.

Authors:  Antonio Tursi; Giovanni Brandimarte; Gian Marco Giorgetti; Walter Elisei
Journal:  J Clin Gastroenterol       Date:  2006-04       Impact factor: 3.062

3.  Timing of prophylactic surgery in prevention of diverticulitis recurrence: a cost-effectiveness analysis.

Authors:  Robert J Richards; James K Hammitt
Journal:  Dig Dis Sci       Date:  2002-09       Impact factor: 3.199

4.  Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon.

Authors:  A Tursi; G Brandimarte; R Daffinà
Journal:  Dig Liver Dis       Date:  2002-07       Impact factor: 4.088

5.  Efficacy of mesalazine in the treatment of symptomatic diverticular disease.

Authors:  Francesco Di Mario; Giovanni Aragona; Gioacchino Leandro; Giuseppe Comparato; Libera Fanigliulo; Lucas G Cavallaro; Giulia M Cavestro; Veronica Iori; Marta Maino; Alì M Moussa; Alessandro Gnocchi; Giancarlo Mazzocchi; Angelo Franzé
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

Review 6.  The pathology of diverticular disease.

Authors:  Linmarie Ludeman; Bryan F Warren; Neil A Shepherd
Journal:  Best Pract Res Clin Gastroenterol       Date:  2002-08       Impact factor: 3.043

7.  Effect of dietary fibre on stools and the transit-times, and its role in the causation of disease.

Authors:  D P Burkitt; A R Walker; N S Painter
Journal:  Lancet       Date:  1972-12-30       Impact factor: 79.321

8.  The natural history of diverticulitis: fact and theory.

Authors:  Martin H Floch; Iona Bina
Journal:  J Clin Gastroenterol       Date:  2004 May-Jun       Impact factor: 3.062

9.  Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group.

Authors:  C Papi; A Ciaco; M Koch; L Capurso
Journal:  Ital J Gastroenterol       Date:  1992-10

10.  Outcome of younger patients with acute diverticulitis.

Authors:  F Hjern; T Josephson; D Altman; B Holmström; C Johansson
Journal:  Br J Surg       Date:  2008-06       Impact factor: 6.939

View more
  7 in total

1.  Preventing recurrent acute diverticulitis with pharmacological therapies.

Authors:  Antonio Tursi
Journal:  Ther Adv Chronic Dis       Date:  2013-11       Impact factor: 5.091

2.  Italian consensus conference for colonic diverticulosis and diverticular disease.

Authors:  Rosario Cuomo; Giovanni Barbara; Fabio Pace; Vito Annese; Gabrio Bassotti; Gian Andrea Binda; Tino Casetti; Antonio Colecchia; Davide Festi; Roberto Fiocca; Andrea Laghi; Giovanni Maconi; Riccardo Nascimbeni; Carmelo Scarpignato; Vincenzo Villanacci; Bruno Annibale
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

Review 3.  Diverticular disease: changing epidemiology and management.

Authors:  Roshan Razik; Geoffrey C Nguyen
Journal:  Drugs Aging       Date:  2015-05       Impact factor: 3.923

Review 4.  Risk factors for recurrence after acute colonic diverticulitis: a systematic review.

Authors:  Line Hupfeld; Jakob Burcharth; Hans-Christian Pommergaard; Jacob Rosenberg
Journal:  Int J Colorectal Dis       Date:  2017-01-22       Impact factor: 2.571

Review 5.  Colonic diverticular disease.

Authors:  Antonio Tursi; Carmelo Scarpignato; Lisa L Strate; Angel Lanas; Wolfgang Kruis; Adi Lahat; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-03-26       Impact factor: 52.329

Review 6.  Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017.

Authors:  Carmelo Scarpignato; Giovanni Barbara; Angel Lanas; Lisa L Strate
Journal:  Therap Adv Gastroenterol       Date:  2018-05-20       Impact factor: 4.409

7.  Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials.

Authors:  Andrea Iannone; Marinella Ruospo; Germaine Wong; Michele Barone; Mariabeatrice Principi; Alfredo Di Leo; Giovanni F M Strippoli
Journal:  Can J Gastroenterol Hepatol       Date:  2018-09-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.